A5020430806- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- PARP inhibition in cancer therapy
- Cancer Research and Treatments
- Platelet Disorders and Treatments
- Complement system in diseases
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- Cancer survivorship and care
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Xenotransplantation and immune response
- Prostate Cancer Treatment and Research
- Animal Genetics and Reproduction
- Cancer-related cognitive impairment studies
- Palliative Care and End-of-Life Issues
- Pregnancy and preeclampsia studies
- Stuttering Research and Treatment
- Dysphagia Assessment and Management
- Neutropenia and Cancer Infections
Cleveland Clinic
2021-2024
University of California, San Diego
2019-2021
Georgetown University
2014-2016
MedStar Georgetown University Hospital
2014-2016
The Ohio State University Wexner Medical Center
2012
Breast cancer survivorship care transitions from active treatment to focus on surveillance and health maintenance. This review article discusses the crucial aspects of breast survivorship, which include surveillance, management side effects, implementation a healthy lifestyle, psychosocial support.
Abstract HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two combinations neoadjuvant I-SPY2 phase 2 adaptive platform trial for cancer at high risk recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel, trastuzumab (THP). Eligible women have >2.5 cm clinical stage II/III HER2 + cancer, adaptively randomized to T-DM1/P, THP, or a common control arm paclitaxel/trastuzumab (TH), followed by...
Abstract Background: CDK7 has 3 critical roles in cancer: enhanced transcription of oncogenes and upregulation anti-apoptotic genes, acceleration the cell cycle through phosphorylation other CDKs driving estrogen receptor (ER) resistance to hormonal therapy. Inhibition is therefore a potential novel anti-cancer therapeutic strategy. Samuraciclib (CT7001), once daily oral inhibitor demonstrated favorable safety profile clinical activity combination with fulvestrant (SERD) patients HR+/HER2-...
191 Background: The incidence of DCIS over the last two decades has increased, with 62,000 new cases diagnosed annually in United States. Tailored management is still a work progress and currently treatment options are varied. We sought to identify changes patterns care individual physician choices for surgery chemoprophylaxis at our institution. Methods: performed retrospective chart review identified 773 eligible patients using James Cancer Registry NCCN database Ohio State University...
Abstract Background: Triple-negative breast cancer (TNBC) has a poor prognosis and may be associated with germline mutations. α-Lactalbumin (aLA) is expressed in lactating breasts but not at other times or tissues. Expression of aLA found 70% TNBC (PMID: 27322324) so could an immunologic target for based on the “retired protein hypothesis” 31926646). In pre-clinical studies, vaccination provided protection from development autochthonous tumors transgenic murine models inhibited growth...
Immunotherapy represents an emerging modality of treatment utilized in patients with prostate cancer, among various other malignancies.Sipuleucel-T is autologous active cellular immunotherapy that has demonstrated improved survival metastatic castration-resistant cancer (mCRPC). The IMPACT trial led to the FDA approval sipuleucel-T as first-line for men asymptomatic or minimally symptomatic mCRPC. Additional immunotherapies have shown promising results clinical studies. These include...
TPS1125 Background: Triple-negative breast cancer (TNBC) is the subtype of with worst prognosis and most often associated germline mutations BRCA1 certain other genes. Alpha-lactalbumin (aLA) a milk protein that expressed in lactating breasts but not at times or normal tissues. Expression aLA found approximately 70% TNBC (Cancers PMID: 27322324) so an attractive immunologic target for based on “retired hypothesis” (Semin Immunol 31926646). Pre-clinical studies have shown vaccination provides...
TPS1102 Background: While immunostimulatory therapies have shown great success, a major challenge remains identification of mechanisms to effectively treat the majority patients with so-called "non-inflamed" tumors lacking marked lymphocyte infiltration and PD-L1 expression. The DNA repair proficiency tumor may impact its potential for immune recognition sensitivity checkpoint blockade. Preclinically, PARP inhibition in HDR-deficient has been trigger antitumor immunity through...
Abstract Background: Triple-negative breast cancer (TNBC) has a poor prognosis and may be associated with germline mutations. α-lactalbumin (aLA) is expressed in lactating breasts but not at other times or tissues. Expression of aLA found 70% TNBC (PMID: 27322324) so could an immunologic target for based on the “retired protein hypothesis” 31926646). In pre-clinical studies vaccination inhibited growth established tumors provided protection from development autochthonous transgenic murine...
Abstract Background: Treatment with endocrine therapy such as tamoxifen has been identified one of the most important variables linked survival among women hormone receptor-positive breast cancer (BC). There is significant risk reduction BC recurrence and mortality at 15 years patients treated for 5 compared to no therapy. Tamoxifen metabolized in liver via multiple cytochrome P (CYP) isoforms. To ensure optimal efficacy tamoxifen, consideration must be given concomitant use other commonly...
<h3>Background</h3> α-Lactalbumin (aLA) is expressed in lactating breasts and 70% of triple-negative breast cancer (TNBC) but not at other times or tissues (PMID: 27322324). Based on the 'retired protein hypothesis' 31926646) vaccination with aLA provided protection from development autochthonous tumors transgenic murine models inhibited growth established 4T1 transplantable BALB/c mice 20512124). <h3>Methods</h3> We are performing a Phase I trial recombinant human GMP-grade zymosan adjuvant...
Abstract Background: I-SPY2 is a multicenter, Phase II trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk at least T2N0 breast cancer. The primary endpoint pathologic complete response (pCR) surgery. goal identify regimens that have ≥ 85% Bayesian predictive probability of success in 300-patient phase 3 defined by hormone-receptor (HR) and HER2 status, MammaPrint (MP). Regimens may leave the futility (&lt;...
e13122 Background: A positive BRCA 1/2 test result can provide young women from hereditary breast cancer (HBC) families with essential information about future risk. While results inform life planning, 5-year risks for are low. Little is known what motivates testing women. the likelihood of should increase as age, it might also familial burden disease (more affected relatives and diagnosed at younger ages). We predicted would age greater burden. Methods: Sixty-one (Mean 23 yrs) who were 1st...
Abstract Background: Triple-negative breast cancer (TNBC) is the subtype of with worst prognosis and most often associated germline mutations BRCA1 as well other genes. Alpha-lactalbumin (aLA) a milk protein expressed in lactating breasts but not at times or normal tissues. Expression aLA found approximately 70% TNBC (Cancers PMID: 27322324) so an attractive immunologic target for based on “retired hypothesis” (Semin Immunol 31926646). Pre-clinical studies have shown that vaccination...